| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2024 |
|
|
2023 |
|
| |
|
Year Ended October 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Net loss: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
(7,388 |
) |
|
$ |
(5,111 |
) |
| CAR-T Therapeutics |
|
|
(5,256 |
) |
|
$ |
(3,879 |
) |
| Other |
|
|
(54 |
) |
|
|
(940 |
) |
| Total |
|
$ |
(12,698 |
) |
|
$ |
(9,930 |
) |
| Net income (loss) |
|
$ |
(12,698 |
) |
|
$ |
(9,930 |
) |
| |
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
13,831 |
|
|
$ |
11,221 |
|
| Less non-cash stock-based compensation |
|
|
(4,782 |
) |
|
|
(4,735 |
) |
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
9,049 |
|
|
$ |
6,486 |
|
| |
|
|
|
|
|
|
|
|
| Operating costs and expenses excluding non-cash stock-based compensation: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
5,235 |
|
|
$ |
3,265 |
|
| CAR-T Therapeutics |
|
|
3,766 |
|
|
|
2,467 |
|
| Other |
|
|
48 |
|
|
|
754 |
|
| Total |
|
$ |
9,049 |
|
|
$ |
6,486 |
|
| Operating
costs and expenses excluding non-cash share based compensation |
|
$ |
9,049 |
|
|
$ |
6,486 |
|
| |
|
2024 |
|
|
|
| |
|
October 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
12,917 |
|
|
$ |
17,215 |
|
| CAR-T Therapeutics |
|
|
8,535 |
|
|
|
7,523 |
|
| Other |
|
|
139 |
|
|
|
784 |
|
| Total |
|
$ |
21,591 |
|
|
$ |
25,522 |
|
| Total assets |
|
$ |
21,591 |
|
|
$ |
25,522 |
|
|